ABCG2 and cancer: Our findings indicate that treatment with furmonertinib at concentrations ranging from 50 nM to 500 nM did not produce a significant impact on the protein expression of ABCB1 in NCI-ADR-RES (Figure 5A) and KB-V1 (Figure 5B) cells, nor on ABCG2 in S1-MI-80 (Figure 5C) and H460-MX20 (Figure 5D) cancer cells over a period of 72 h.